Last €0.51 EUR
Change Today -0.0155 / -2.94%
Volume 616.0K
MLM On Other Exchanges
As of 8:07 AM 09/23/14 All times are local (Market data is delayed by at least 15 minutes).

molecular medicine spa (MLM) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/13/14 - €0.88
52 Week Low
08/8/14 - €0.47
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for MOLECULAR MEDICINE SPA (MLM)

Related News

No related news articles were found.

molecular medicine spa (MLM) Related Businessweek News

No Related Businessweek News Found

molecular medicine spa (MLM) Details

MolMed S.p.A., a medical biotechnology company, focuses on the research, development, and clinical validation of therapies to treat cancer. Its products include TK, a cell therapy product, which is in Phase III clinical trials enabling safe transplant of haematopoietic stem cells from partially compatible haplo-identical donors for the treatment of haematological malignancies. The company’s products also comprise NGR-hTNF, a recombinant biological drug that is in Phase II clinical trials for various types of solid tumours, such as colorectal, hepatocellular carcinoma and mesothelioma, small-cell lung cancer, non-small cell lung cancer, ovarian cancer, and soft-tissue sarcoma, as well as is in Phase III clinical trials in mesothelioma patients. It has an agreement with Telethon Foundation for the co-development and clinical-grade manufacture of gene therapies for rare genetic diseases; San Raffaele Foundation for the clinical-grade manufacturing of a cell therapy for Duchenne muscular dystrophy; and GlaxoSmithKline for the development and production for clinical use of a viral vector for ADA, as well as a strategic partnership with Takara Bio, Inc. for TK cell therapy. The company was founded in 1996 and is based in Milan, Italy.

Founded in 1996

molecular medicine spa (MLM) Top Compensated Officers

Founder, Chairman, Chairman of the Scientific...
Total Annual Compensation: €771.0K
General Manager of R&D & Operations and Execu...
Total Annual Compensation: €390.0K
Business Development and Ir Director, General...
Total Annual Compensation: €399.0K
Compensation as of Fiscal Year 2012.

molecular medicine spa (MLM) Key Developments

MolMed S.p.A., Special/Extraordinary Shareholders Meeting, Sep 08, 2014

MolMed S.p.A., Special/Extraordinary Shareholders Meeting, Sep 08, 2014.

MolMed S.p.A. to Report First Half, 2014 Results on Jul 31, 2014

MolMed S.p.A. announced that they will report first half, 2014 results on Jul 31, 2014

MolMed S.p.A., Board Meeting, Jul 31, 2014

MolMed S.p.A., Board Meeting, Jul 31, 2014. Agenda: To consider approval of first half-year report for the period ended June 30, 2014.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MLM:IM €0.51 EUR -0.0155

MLM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for MLM.
View Industry Companies

Industry Analysis


Industry Average

Valuation MLM Industry Range
No financial data is available for MLM.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MOLECULAR MEDICINE SPA, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at